US Case Report
Journal of Generic Medicines (2007) 5, 53–64. doi:10.1057/palgrave.jgm.4950090; published online 14 August 2007
Pfizer v Apotex: What is the current standard of obviousness under 35 USC § 103?
Compiled and written by Goodwin Procter LLP
The Life Sciences Practice at Goodwin Procter LLP provides dedicated, industry-focused
representation of life sciences companies at all stages, from start-up through to
mature public company, with the full range of representation, including:
Legal advice on corporate intellectual property matters
Patent portfolio development
Intellectual property litigation
In-licensing and out-licensing of intellectual property
Corporate finance transactions
Research and development (R&D) collaborations
Negotiating merger and acquisition (M&A) transactions
Defending against product liability claims
The views expressed in this paper are solely the authors', based on publicly available information.
This paper does not present the views of any former or present client of Goodwin Procter LLP.
This section is intended to be a synopsis of recent developments and is not intended to be exhaustive. If
any issue in this section is to be relied upon, specific advice should be sought. Please contact the Editor:
Frederick H. Rein
Partner
Goodwin Procter LLP
599 Lexington Avenue
New York, NY 10022
USA
Tel: +1 212 813 8864
Fax: +1 212 355 3333
Email: frein@goodwinprocter.com
Godwin Procter LLP is based in the USA with offices in Boston, Los Angeles, New York, San Francisco,
Palo Alto, California and Washington DC.
Frederick H Rein1 and Joseph B Crystal2
1is a partner at Goodwin Procter LLP
2is an associate at Goodwin Procter LLP
